City analysts understand the companies they cover better than anyone - so it can pay to take note of their trading recommendations. 'Buy', 'hold' and 'sell' ratings can be a useful signal when it comes to deciding whether to buy a shar...
CLIN — Clinigen Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid CapNeutral
- £1.73bn
- £2.07bn
- £523.60m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.51 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | 1.1% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 302.3 | 381.2 | 456.9 | 466.7 | 523.6 | 556.54 | 611.09 | 9.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +17.4 | +14.21 | +15.78 | +13.65 | -29.64 | +69.65 | +13.6 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for CLIN
Broker recommendations can be a useful early clue in the hunt for stocks to add to your portfolio. These city analysts know the companies they cover better than most, so their views on whether to buy or sell them are worth considering....
The Clinigen (LON:CLIN) share price has risen by 5.63% over the past month and it’s currently trading at 637.5p. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue...
Broker research is an important consideration in the strategies of many investors. Reading up on what the experts think - and examining whether they believe a share is a 'buy', 'hold' or 'sell' - can be very useful. For investors, thes...
Company analysts usually understand the stocks they cover better than just about anyone else. For that reason, it can be useful to know whether they think investors should 'buy', 'hold' or 'sell' them. These kinds of clues can give you...
Profile Summary
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Directors
- Elmar Schnee NEC (62)
- Shaun Chilton CEO (51)
- Richard Paling CFO
- Sam Herbert COO
- Amanda Miller GCN
- Alan Boyd NED (65)
- Sharon Curran NID
- Anne Hyland NID
- Ian Johnson NID (62)
- Ian Nicholson NID (56)
- Last Annual
- June 30th, 2021
- Last Interim
- June 30th, 2021
- Incorporated
- December 12th, 2008
- Public Since
- September 25th, 2012
- No. of Employees
- 1,013
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 133,366,726
- Address
- Pitcairn House, BURTON UPON TRENT, DE14 2WW
- Web
- https://www.clinigengroup.com/
- Phone
- +44 1283495010
- Auditors
- PricewaterhouseCoopers LLP
Latest News for CLIN
Upcoming Events for CLIN
Half Year 2022 Clinigen Group PLC Earnings Release
Similar to CLIN
4Basebio
London Stock Exchange
4d Pharma
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
FAQ
What is the Clinigen share price?
As of Today at 07:18 UTC, shares in Clinigen are trading at 782.50p. This share price information is delayed by 15 minutes.
How has the Clinigen share price performed this year?
Shares in Clinigen last closed at 782.50p and the price had moved by +22.17% over the past 365 days. In terms of relative price strength the Clinigen share price has outperformed the FTSE All Share Index by +11.23% over the past year.
What are the analyst and broker recommendations for Clinigen?
The overall consensus recommendation for Clinigen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Clinigen dividend yield?
The Clinigen dividend yield is 0.97% based on the trailing twelve month period.
Does Clinigen pay a dividend?
Last year, Clinigen paid a total dividend of £0.08, and it currently has a trailing dividend yield of 0.97%.Looking ahead, the next dividend pay date is 2022-01-04.
When does Clinigen next pay dividends?
We do not have data on when Clinigen is to next pay dividends. The historic dividend yield on Clinigen shares is currently 0.97%.
How do I buy Clinigen shares?
To buy shares in Clinigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clinigen?
As of the previous close price of 782.50p, shares in Clinigen had a market capitalisation of £1.73bn.
Where are Clinigen shares listed?
Here are the trading details for Clinigen:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CLIN
What kind of share is Clinigen?
Based on an overall assessment of its quality, value and momentum Clinigen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clinigen share price forecast for 2021?
The analyst consensus target price for shares in Clinigen is 762.26p. That is 2.59% below the last closing price of 782.50p.
Analysts covering Clinigen currently have a consensus Earnings Per Share (EPS) forecast of £0.55 for the next financial year.
What is the trend in the Clinigen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinigen. Over the past six months, its share price has outperformed the FTSE All Share Index by +26.76%.
As of the last closing price of 782.50p, shares in Clinigen were trading +13.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clinigen PE Ratio?
The Clinigen PE ratio based on its reported earnings over the past 12 months is 13.51. The shares last closed at 782.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clinigen?
Clinigen's management team is headed by:
- Elmar Schnee - NEC
- Shaun Chilton - CEO
- Richard Paling - CFO
- Sam Herbert - COO
- Amanda Miller - GCN
- Alan Boyd - NED
- Sharon Curran - NID
- Anne Hyland - NID
- Ian Johnson - NID
- Ian Nicholson - NID